Acambis: Can Smallpox Sustain?

The UK's Acambis became one of a handful of European biotechs to post profits this year, boosted by a US government smallpox vaccine contract worth $428 million. The profitability label is a useful one these days: cautious investors find it easier to swallow R&D risk if accompanied by earnings. And Acambis' management has promised it can keep the company in the black, defying the skeptics. Near-term, it will leverage its smallpox franchise to secure further, and extended, government contracts. Beyond that, Acambis' pipeline of relatively low-risk products should start to come to fruition.

Acambis PLC 's progression to profitability is about opportunities spotted and seized, focus and luck. Buying US group OraVax in 1998 was probably the company's shrewdest single move [See Deal]. It focused the group's activities on vaccines, an increasingly high growth area, providing two safe, effective technologies that underlie most of Acambis' current pipeline. OraVax also had a manufacturing plant on the East Coast, which Acambis initially tried to sell, since it had been idle for five years. There were no buyers at the time—luckily, as it turned out.

Production capacity and a US presence helped Acambis win its first US government smallpox vaccine in September 2000, worth $343 million (€305 million). Acambis agreed to provide 40 million doses...

More from Global Vision

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.